A carregar...
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ibrutinib has significantly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). Recent reports attribute ibrutinib resistance to acquired mutations in Bruton agammaglobulinemia tyrosine kinase (BTK), the target of ibrutinib, as well as the immediate downstream effector...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492196/ https://ncbi.nlm.nih.gov/pubmed/25972157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-626846 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|